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Background and purpose — Smoking is a modifiable 
risk factor that may adversely affect postoperative outcomes. 
Healthcare providers are increasingly denying smokers 
access to total hip and knee arthroplasty (THA and TKA) 
until they stop smoking. Evidence supporting this is unclear. 
We assessed the effect of smoking on outcomes following 
arthroplasty.
Patients and methods — We identified THAs and 
TKAs from the Clinical Practice Research Datalink, which 
were linked with datasets from Hospital Episode Statistics 
and the Office for National Statistics to identify outcomes. 
The effect of smoking on postoperative outcomes (compli-
cations, medications, revision, mortality, patient-reported 
outcome measures [PROMs]) was assessed using adjusted 
regression models.
Results — We studied 60,812 THAs and 56,212 TKAs 
(11% smokers, 33% ex-smokers, 57% non-smokers). Fol-
lowing THA, smokers had an increased risk of lower respi-
ratory tract infection (LRTI) and myocardial infarction 
compared with non-smokers and ex-smokers. Following 
TKA, smokers had an increased risk of LRTI compared with 
non-smokers. Compared with non-smokers (THA relative 
risk ratio [RRR] = 0.65; 95% CI = 0.61–0.69; TKA RRR = 
0.82; CI = 0.78–0.86) and ex-smokers (THR RRR = 0.90; 
CI = 0.84–0.95), smokers had increased opioid usage 1-year 
postoperatively. Similar patterns were observed for weak 
opioids, paracetamol, and gabapentinoids. 1-year mortality 
rates were higher in smokers compared with non-smokers 
(THA hazard ratio [HR] = 0.37, CI = 0.29–0.49; TKA HR = 
0.52, CI = 0.34–0.81) and ex-smokers (THA HR = 0.53, CI 
= 0.40–0.70). Long-term revision rates were not increased in 
smokers. Smokers had improvement in PROMs compared 
with preoperatively, with no clinically important difference 
in postoperative PROMs between smokers, non-smokers, 
and ex-smokers.
Interpretation — Smoking is associated with more medi-
cal complications, higher analgesia usage, and increased 
mortality following arthroplasty. Most adverse outcomes 
were reduced in ex-smokers, therefore smoking cessation 
should be encouraged before arthroplasty.
Total hip arthroplasty (THA) and total knee arthroplasty 
(TKA) are well established clinically and are cost-effective 
interventions for treating symptomatic arthritis (Learmonth et 
al. 2007). These procedures are commonly performed world-
wide, with numbers predicted to increase (Culliford et al. 
2015).
The UK National Health Service is currently under unprece-
dented financial pressures (Daily Telegraph 2018). In the UK, 
197 clinical commissioning groups (CCGs) have the author-
ity and funding to commission healthcare services for their 
communities. In recent years over half of CCGs have rationed 
THA and TKA to reduce healthcare expenditure; therefore 
patients with certain perceived risk factors (like smokers, or 
those with a high BMI) have been denied access to arthro-
plasty (Daily Telegraph 2018). A recent report highlighted 
the severity of the problem with almost 1,700 requests for 
THA and TKA rejected by CCGs between 2017 and 2018, 
which represented a 45% increase from the previous year with 
some CCGs rejecting almost all requests received (Iacobucci 
2018a). These actions leave many patients in considerable 
pain for prolonged periods despite a clinically effective inter-
vention being available, and it appears patients are increas-
ingly accessing arthroplasty in the private sector (Iacobucci 
2018a). Thus, the longstanding problem of health inequalities 
between socioeconomic groups is perpetuated.
Rationing of THA and TKA has been strongly discouraged 
by surgical bodies (Royal College of Surgeons 2016, British 
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Orthopaedic Association [BOA] 2017). NICE (2017) recom-
mends patient-specific factors (including age, sex, smoking, 
obesity, and comorbidities) should not be barriers to referral for 
arthroplasty. Smoking is a modifiable risk factor that is often 
perceived to adversely affect outcomes following surgery. How-
ever, there is insufficient evidence to support the CCGs’ stance 
of denying current smokers access to arthroplasty. Studies of 
arthroplasty patients have observed that, compared with non-
smokers, smokers have increased wound complications, deep 
infection, chest infection, implant revision, hospital readmis-
sion, and mortality (Singh 2011, Duchman et al. 2015, Singh et 
al. 2015, Teng et al. 2015, Bohl et al. 2016, Tischler et al. 2017). 
However, these observations were not consistent between the 
different studies, with some studies reporting no effect of smok-
ing on these same outcome measures (Inoue et al. 1999, Malik 
et al. 2004, Sadr Azodi et al. 2008, Musallam et al. 2013, Maoz 
et al. 2015, Cunningham et al. 2017, Sahota et al. 2018). The 
inconsistent findings of studies into the effect of smoking on 
outcomes following arthroplasty might be explained by their 
numerous limitations including the analysis of small cohorts, 
not separating THA and TKA patients for analysis, limited or 
no adjustment for confounding factors, providing only short-
term outcomes, and not assessing the effect of previous smok-
ing on outcomes. Furthermore, many studies have not reported 
on important outcomes, like postoperative analgesia usage and 
patient-reported outcome measures (PROMs), which have not 
been assessed in large cohorts. The latter is pertinent given 
that clinically meaningful improvement in PROMs following 
arthroplasty is key in deciding whether or not to recommend 
joint replacement to patients (Wallace et al. 2014). Therefore it 
is difficult to support the implementation of a policy that denies 
access to arthroplasty for smokers based on current evidence.
This population-based cohort study assesses the effect of 
smoking and cessation of smoking on postoperative outcomes 
following THA and TKA. For completeness we have studied 
complications, medication usage, hospital readmission, revi-
sion surgery, mortality, and PROMs in smokers, ex-smokers, 
and non-smokers.
Patients and methods
Patients were initially identified using the Clinical Practice 
Research Datalink (CPRD) GOLD, which has been described 
previously (Bayliss et al. 2017). CPRD represents one of the 
largest databases of longitudinal primary care medical records 
worldwide. It contains anonymized patient data from 4% of 
the current UK population (over 2 million patients from 269 
contributing practices) (Herrett et al. 2015). Practices’ spread 
ensures CPRD is representative of the wider UK population 
for age, sex, and ethnicity. Read Codes are used to enter clini-
cal information (medical history, prescription data, hospital 
admissions, and interventions), which are standard clinical 
terminologies used within UK primary care (Benson 2011). 
CPRD therefore provides a detailed record of both primary 
and secondary care (Bayliss et al. 2017). The validity and 
quality of data captured within CPRD have been previously 
well described (Herrett et al. 2015). A systematic review of 
validation studies assessing the validity of diagnoses in CPRD 
identified a large number of studies across a wide range of 
over 183 different diagnoses and overall estimates of validity 
were high (Herrett et al. 2010). Aspects of data quality in Eng-
lish primary care are enhanced by the Quality and Outcomes 
Framework, an incentive payment program for primary care 
physicians, which encourages recording of key data items (for 
example smoking status). 
Where available, primary care records from CPRD were 
linked to secondary care admission records from Hospital Epi-
sodes Statistics Admitted Patient Care data (HES) and to the 
Office for National Statistics (ONS) database. HES uses Inter-
national Classification of Diseases 10th revision (ICD-10) 
records diagnoses and the Office of Population Censuses and 
Surveys version 4 (OPCS-4) procedures to record diseases, 
complications, interventions, and procedures from secondary 
care. From April 1, 2009, HES provided PROMs data before 
and 6 months following THA and TKA (see below). The ONS 
provides data on all-cause mortality. 
Population
All patients aged 18 years and older in CPRD with a diag-
nostic code for primary THA or TKA between January 1, 
1995 and January 28, 2017 were identified using previously 
validated Read Codes (Culliford et al. 2012, 2015). Patients 
were eligible for inclusion if their record was labelled accept-
able by CPRD quality control (Herrett et al. 2015), approved 
for CPRD, HES, ONS linkage, and if the patient was regis-
tered with their general practice for at least 12 months (n = 
136,410). Patients were excluded if data on the exposure vari-
able were missing (n = 19,386) leaving 117,024 patients for 
analysis (Appendix 1). The study exposure, covariates, and 
outcomes were identified from the various linked databases 
using ICD-10 codes, OPCS-4 operation codes, Product Code 
lists for prescribed medications and Read Codes.
Exposure
The study exposure was patient smoking status as classified in 
CPRD at the time of arthroplasty: current smoker, ex-smoker, 
and non-smoker. Studies specifically assessing the quality 
of smoking data within CPRD demonstrate prevalence esti-
mates for current smoking and non-smoking that are similar to 
those from nationally representative surveys, although former 
smoking may be under-recorded (Booth et al. 2013).
Covariates
CPRD contains numerous patient-related covariates, which 
were subsequently adjusted for. These included age, sex, BMI, 
socioeconomic status, alcohol consumption, year of surgery, 
and pre-existing comorbidities (including cardiovascular, 
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respiratory, and cerebrovascular diseases, renal failure, cancer, 
inflammatory arthritis, diabetes). BMI was categorized as 
underweight (≥10 and <18.5); normal (≥18.5 and <25 ); over-
weight (≥25 and <30 ); obese class I (≥30 and <35 ); obese 
class II (≥35 and <40 ); and obese class III (≥40 and ≤60 ). 
Socioeconomic status was classified using the Index of Multi-
ple Deprivation (IMD), as described previously (Conrad et al. 
2018). Patients were divided into 10 equal groups ranked from 
1 (least deprived area) to 10 (most deprived area) (Department 
for Communities and Local Government [DCLG] 2015). The 
Charlson Comorbidity Index was calculated for each patient 
based on pre-existing comorbidities. Preoperative PROMs 
were available for a subgroup of patients (detailed below).
Outcomes
Postoperative outcomes of interest were: complications, mor-
tality, medication usage, hospital readmission, revision sur-
gery, and PROMs. All outcome data were collected using a 
combination of CPRD and HES apart from mortality, which 
was obtained from CPRD and ONS. Complications were 
recorded within 6 months of surgery, and included cerebro-
vascular events, myocardial infarction, ischemic heart disease, 
deep vein thrombosis, pulmonary embolism, lower respira-
tory tract infection (LRTI), urinary tract infection, and wound 
infection. Medications prescribed (which included analgesia 
requirements) and hospital readmissions within 1 year of sur-
gery were recorded. Revision surgery was defined as removal 
or exchange or addition of any implant(s), within 20 years 
of surgery. Mortality was assessed 1 year postoperatively. 
PROMs at 6 months following surgery were available in a 
subgroup of patients, which are collected as part of a national 
PROMs program. These joint-specific (Oxford Hip Score 
[OHS] and Oxford Knee Score [OKS]) PROMs are validated 
measures for assessing outcomes following arthroplasty. They 
are scored from 0 (worst) to 48 (best). The change in score 
following arthroplasty was calculated by subtracting the pre-
operative score from the 6-month postoperative score. The 
minimally important clinical differences are 5 points for the 
OHS and 4 points for the OKS (Beard et al. 2015).
The validity of coding of complications has been previ-
ously assessed and known to be good (Wallace et al. 2014). 
Mortality rates within CPRD are comparable to rates in the 
National Joint Registry (NJR) annual reports (NJR 2018). 
Data on revision and readmission come from linked data from 
HES records, and the validity of coding between NJR and 
HES records has previously been described in NJR annual 
reports and data quality audits (NJR 2018). Furthermore vali-
dation studies of joint replacement records in CPRD and HES 
showed high levels of agreement (Hawley et al. 2016).
Statistics
We assessed the effect of smoking status on binary outcomes 
(complications, medication usage, and readmissions) by fit-
ting a generalized linear model with a binomial error structure 
and a log link function (log-logistic model), where results are 
presented as relative risk ratios (RRR). Models were adjusted 
for potential confounding factors (age, sex, BMI, IMD, alcohol 
consumption, year of surgery, and the Charlson Comorbidity 
Index). Cumulative implant and patient survival rates following 
arthroplasty were determined using Kaplan–Meier estimates. 
Patients who were alive with an arthroplasty not requiring revi-
sion surgery were censored on the study end date. The asso-
ciations between smoking status with implant and patient sur-
vival rates were explored using Cox regression analysis, with 
models adjusted for confounders (see above). The confounders 
we adjusted for were selected a priori given that they have been 
shown to affect the study exposure, outcomes, and/or access to 
healthcare (Hunt et al. 2013, 2014, Wallace et al. 2014, Kunut-
sor et al. 2016, AOANJRR 2018, Edwards et al. 2018). Pro-
portional hazards assumptions were assessed and satisfied for 
all regression analyses. We used an ANCOVA linear regres-
sion model to look at predictors of the obtained 6-month OHS 
and OKS, adjusting for the baseline score. To look at changes 
in scores between baseline and follow-up we fitted a repeated 
measures regression model where the outcome was expanded 
to include the preoperative and 6-month postoperative OHS or 
OKS. Interaction terms were fitted between the predictor vari-
able and time, to describe the change in OHS and OKS over 
time across categories of the predictor variable smoking. We 
used robust standard errors with the sandwich variance estima-
tor given there was evidence of heteroscedasticity. All models 
were based on complete case analysis. All statistical analyses 
were performed with Stata Statistical Software release version 
IC 15.0, 2017 (StataCorp, Stata College Station, TX, USA). 
Ethics, funding, and potential conflicts of interest
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ported by the NIHR Biomedical Research Centre at the Uni-
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also received personal fees for undertaking medicolegal work 
for Leigh Day. SM, ST, and AD have no relevant conflicts of 
interest. AJ has received consultancy fees from Freshfields 
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and monitoring board for Anthera Pharmaceuticals. DWM 
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institutional research grants from UKIERI, Charnley Trust, 
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Results
We studied 117,024 patients undergoing arthroplasty (60,812 
THAs and 56,212 TKAs) with details available on smoking 
status (12,644 (11%) smokers, 38,148 (33%) ex-smokers, and 
66,232 (57%) non-smokers) (Tables 1 and 2).
Complications
Following THA, smokers had an increased risk of myocardial 
infarction and LRTI compared with both non-smokers and ex-
smokers (Figure 1; Appendix 2 and 3). Smokers had a similar 
risk of wound infection and thromboembolic events compared 
with non-smokers and ex-smokers following THA as well 
as TKA. Following TKA, only LRTI was more commonly 
observed in smokers compared with non-smokers (RRR = 
0.66, CI 0.52–0.83) (Figure 2; Appendix 3 and 4).
Medication usage
Within 1 year of THA, smokers had increased use of opioids 
compared with non-smokers (RRR = 0.65; CI 0.61–0.69) and 
ex-smokers (RRR = 0.90; CI 0.84–0.95) (Figure 1; Appendix 
2 and 3). Smokers also had increased use of weak opioids, 
Table 1. Demographics of patients undergoing total hip arthro-
plasty. Values are frequency (%) unless otherwise stated
Confounder Smoker Non-smoker Ex-smoker
Total 7,543 (12) 34,271 (56) 18,998 (31)
Male 3,059 (41) 11,343 (33) 9,343 (49)
Female 4,484 (59) 22,928 (67) 9,655 (51)
Age, mean (SD) 63 (12) 70 (11) 70 (10)
BMI      
 Underweight 228 (3.7) 526 (1.8) 227 (1.4)
 Normal 2,118 (34) 8,692 (30) 3,913 (23)
 Overweight 2,217 (36) 11,771 (40) 6,866 (41)
 Obese class I 1,140 (19) 5,852 (20) 4,015 (24)
 Obese class II 365 (5.9) 1,849 (6.3) 1,356 (8.1)
 Obese class III 110 (1.8) 607 (2.1) 392 (2.3)
 Missing 1,365   4,974   2,229  
Charlson score 1 year a      
 0 6,962 (92) 31,437 (92) 16,874 (89)
 1 325 (4.3) 1,398 (4.1) 1,052 (5.5)
 2 206 (2.7) 1,148 (3.3) 803 (4.2)
 ≥ 3 50 (0.7) 288 (0.8) 269 (1.4)
Deprivation Index rank       
 1 416 (9.6) 3,446 (17) 1,574 (14)
 2 418 (9.7) 2,862 (14) 1,453 (13)
 3 436 (10) 2,697 (13) 1,444 (13)
 4 469 (11) 2,552 (12) 1,387 (12)
 5 488 (11) 2,590 (13) 1,480 (13)
 6 418 (9.7) 1,908 (9.2) 1,092 (9.4)
 7 389 (9.0) 1,635 (7.9) 995 (8.6)
 8 402 (9.3) 1,283 (6.2) 882 (7.6)
 9 426 (9.9) 959 (4.6) 675 (5.8)
 10 461 (11) 756 (3.7) 599 (5.2)
 Missing 3,220   13,583   7,417 
Alcohol consumption   
 Yes 4,691 (80) 21,151 (78) 13,029 (84)
 No 898 (15) 5,628 (21) 1,854 (12)
 Ex 243 (4.2) 530 (1.9) 555 (3.6)
 Missing 1,711  6,962  3,560 
Year of surgery   
 1995–2000 738 (9.8) 2,980 (8.7) 736 (3.9)
 2001–2010 4,291 (57) 18,864 (55) 10,710 (56)
 2011–2016 2,514 (33) 12,427 (36) 7,552 (40)
Preoperative Oxford Hip Score
 median (IQR) 16 (11–21) 18 (13–24) 18 (12–24)
a
 Charlson index score based on comorbidities 1 year prior to index 
date. 
Table 2. Demographics of patients undergoing total knee arthro-
plasty. Values are frequency (%) unless otherwise stated
Confounder Smoker Non-smoker Ex-smoker
Total 5,101 (9.1) 31,961 (57) 19,150 (34)
Male 2,597 (51) 10,910 (34) 10,997 (57)
Female 2,504 (49) 21,051 (66) 8,153 (43)
Age, mean (SD) 64 (10) 70 (10) 70 (9)
BMI      
 Underweight 44 (1.0) 138 (0.5) 63 (0.4)
 Normal 844 (20) 4,811 (17) 2,300 (13)
 Overweight 1,628 (38) 10,567 (38) 6,696 (39)
 Obese class I 1,144 (26) 7,744 (28) 5,179 (30)
 Obese class II 488 (11) 3,526 (13) 2,162 (13)
 Obese class III 178 (4.1) 1,390 (4.9) 855 (5.0)
 Missing 775   3,785  1,895 
Charlson score 1 year a       
 0 4,646 (91) 28,994 (91) 16,985 (89)
 1 249 (4.9) 1,451 (4.5) 1,062 (5.5)
 2 161 (3.2) 1,190 (3.7) 857 (4.5)
 ≥ 3 45 (0.9) 326 (1.0) 246 (1.3)
Deprivation Index rank       
 1 253 (8.2) 2,932 (15) 1,496 (13)
 2 272 (8.8) 2,396 (12) 1,407 (12)
 3 276 (8.9) 2,427 (12) 1,459 (12)
 4 310 (10) 2,455 (13) 1,431 (12)
 5 358 (12) 2,363 (12) 1,451 (12)
 6 312 (10) 1,907 (9.7) 1,208 (10)
 7 320 (10) 1,709 (8.7) 1,033 (8.7)
 8 328 (11) 1,445 (7.3) 982 (8.2)
 9 310 (10) 1,092 (5.5) 764 (6.4)
 10 357 (12) 964 (4.9) 705 (5.9)
 Missing 2,005   12,271   7,214  
Alcohol consumption    
 Yes 3,129 (79) 19,436 (75) 13,348 (85)
 No 660 (17) 5,809 (23) 1,859 (12)
 Ex 173 (4.4) 550 (2.1) 570 (3.6)
 Missing 1,139  6,166  3,373 
Year of surgery    
 1995–2000 357 (7.0) 1,917 (6.0) 524 (2.7)
 2001–2010 3,074 (60) 18,115 (57) 11,101 (58)
 2011–2016 1,670 (33) 11,929 (37) 7,525 (39)
Preoperative Oxford Knee Score
 median (IQR) 17 (12–23) 19 (14–25) 20 (14–25)
a
 Charlson index score based on comorbidities 1 year prior to index 
date.  
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paracetamol, and gabapentinoids compared with both non-
smokers and ex-smokers following THA. Similar patterns of 
increased analgesia use in smokers were observed following 
TKA (Figure 2; Appendix 3 and 4).
Readmission
The risk of hospital readmission in smokers following THA 
was higher compared with non-smokers, but not compared 
with ex-smokers (Figure 1). The risk of hospital readmission 
was not affected by smoking status following TKA (Figure 2).
Revision surgery
The risk of revision up to 20 years following THA was similar 
in smokers compared with non-smokers (hazard ratio (HR) = 
1.1; CI 0.88–1.5) and ex-smokers (HR = 1.1; CI 0.84–1.5). 
The risk of revision following TKA was similar in smokers 
compared with non-smokers (HR = 1.2; CI 0.90–1.6) and ex-
smokers (HR 1.1; CI = 0.78–1.4).
Mortality
Following THA, 1-year mortality rates were higher in smok-
ers compared with non-smokers (HR = 0.37, CI 0.29–0.49) 
and ex-smokers (HR = 0.53, CI 0.40–0.70) (Figure 3). Fol-
lowing TKA, 1-year mortality rates were higher in smokers 
compared with non-smokers only (HR = 0.52, CI 0.34–0.81), 
Figure 1. Forest plot for complications and medication usage following 
total hip arthroplasty by smoking status. The respective relative risk 
ratios and 95% confidence intervals are provided in Appendix 3.
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Figure 2. Forest plot for complications and medication usage following 
total knee arthroplasty by smoking status. The respective relative risk 
ratios and 95% confidence intervals are provided in Appendix 3.
Figure 3. Cumulative probability of mortality up to 1 year following total 
hip arthroplasty.
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but not compared with ex-smokers (HR = 0.71, CI 0.46–1.1) 
(Figure 4).
Patient-reported outcome measures
PROMs were available for 10,009 (8.6%) patients. Smokers 
had improvement in PROMs compared with the preoperative 
scores (Figures 5 and 6, and Appendix 5). Smokers undergo-
ing THA and TKA had lower postoperative PROMs compared 
with non-smokers and ex-smokers; however, these differences 
were not clinically meaningful. Following THA, smokers had 
lower postoperative OHSs compared with non-smokers (mean 
2.5 points; CI 1.5–3.5) and ex-smokers (mean 1.8 points; CI 
0.79–2.9). Following TKA, smokers had lower postoperative 
OKSs compared with non-smokers (mean 3.2 points; CI 2.0–
4.5) and ex-smokers (mean 2.9 points; CI 1.7–4.2).
Discussion
Smoking was associated with an increased risk of medical 
complications, increased analgesia usage, and higher mortal-
ity following arthroplasty. 
The increased risk of LRTI (Bohl et al. 2016) and cardio-
vascular complications (Ockene and Miller 1997, Hunt et 
al. 2017) in smokers undergoing arthroplasty in this study 
was similar to previous observations. However, there was no 
increased risk of cardiovascular complications following TKA 
in smokers compared with ex-smokers and non-smokers, 
which could represent selection bias for undergoing these pro-
cedures. Contrary to some studies (Duchman et al. 2015, Bohl 
et al. 2016, Sahota et al. 2018), we found no increase in wound 
infections in smokers following arthroplasty, and the risks of 
venous thromboembolism were similar between groups. The 
differences in cohort size and study design may explain some 
of these findings, including our separate analyses for THA 
and TKA, and differences in follow-up period. Previous stud-
ies have assessed outcomes at 30 days (Duchman et al. 2015, 
Sahota et al. 2018) despite needing at least 90 days to report 
postoperative infections (Centers for Disease Control 2018). 
Arthroplasty patients who smoked had higher 1-year mortality 
rates compared with non-smokers and ex-smokers (the latter 
for THA only), with similar observations reported previously 
(Singh et al. 2011, Clement et al. 2012). However, it is recog-
nized that mortality rates for smokers in the general popula-
tion are known to be 2 to 3 times higher compared with non-
smokers (Thun et al. 2013, Carter et al. 2015).
Increased opioid usage in smokers following arthroplasty 
has been reported (Kim et al. 2017, Cryar et al. 2018). Within 1 
year of arthroplasty we observed increased use of paracetamol, 
non-steroidal anti-inflammatory drugs, weak opioids (includ-
ing codeine), strong opioids (including morphine), and gaba-
pentinoids in smokers compared with non-smokers. This is 
concerning given the current worldwide opioid epidemic (Brat 
et al. 2018) coupled with the projected increase in arthroplasty 
(Culliford et al. 2015). This poses significant public health 
risks including the development of opioid dependence and 
opioid-related deaths (Brat et al. 2018). All clinicians must 
therefore remain cognizant of the increased analgesic needs of 
smokers following arthroplasty and use non-opioid medica-
tions when possible.
Smokers had a similar risk of long-term revision (at up to 
20 years postoperatively) compared with non-smokers and ex-
smokers. Other studies observing an increased revision risk 
have focused on short-term outcomes (Duchman et al. 2015, 
Teng et al. 2015). Furthermore, smokers obtained clinically 
meaningful PROM improvement following arthroplasty, with 
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Figure 4. Cumulative probability of mortality up 
to 1 year following total knee arthroplasty.
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postoperative PROMs comparable with non-smokers and ex-
smokers. Other smaller studies have suggested that smoking 
does not adversely influence postoperative PROMs (Fisher et 
al. 2007, Khan et al. 2009). Our findings therefore suggest that 
arthroplasty is clinically effective in smokers, which is impor-
tant to recognize given the increasing pressures from some 
healthcare providers to deny arthroplasty to patients who con-
tinue to smoke (RCS 2016, BOA 2017, Iacobucci 2018a).
Most adverse outcomes, namely complications and mortal-
ity, in smokers (versus non-smokers) were not seen in ex-smok-
ers. This suggests that stopping smoking prior to arthroplasty 
may reduce postoperative risks. Fewer studies have assessed 
the effect of cessation of smoking (ex-smoking) on outcomes 
following arthroplasty (Singh 2011). These previous studies 
generally suggest that ex-smoking can still be associated with 
complications and mortality following arthroplasty. However, 
this variance could again relate to methodological differences 
between our study and previous work. 
The question of whether or not smokers should quit before 
arthroplasty raises an important ethical dilemma. On one hand 
there is a proven and clinically effective operation available 
that can substantially reduce the pain and disability associ-
ated with hip and knee arthritis. On the other hand, by pro-
ceeding with elective arthroplasty in current smokers there 
are increased risks related to postoperative medical complica-
tions, mortality, and analgesia usage, which are all arguably 
avoidable. 
An early randomized controlled trial reported fewer postop-
erative complications in smokers who either quit or reduced 
their smoking by 50% prior to THA and TKA compared with 
those continuing to smoke (Moller et al. 2002). Subsequently 
strong evidence has been published regarding the benefits of 
various smoking cessation methods before surgery (Myers et 
al. 2011, Thomsen et al. 2014). The latest Cochrane review, 
which included 13 trials assessing smoking cessation, con-
cluded that preoperative smoking interventions, which pro-
vide behavioral support and offer nicotine replacement ther-
apy, can increase cessation in the short term and may reduce 
postoperative morbidity (Thomsen et al. 2014). Although the 
optimal preoperative intensity remains unknown, the authors 
suggested that interventions beginning 4 to 8 weeks before 
surgery, including weekly counselling and nicotine replace-
ment therapy, were more likely to have an impact on compli-
cations and on long–term smoking cessation. 
On the basis of our data and the existing literature we recom-
mend that healthcare professionals actively promote smoking 
cessation preoperatively in patients eligible for arthroplasty, 
as this will prevent the increased surgical risk associated with 
smoking and ultimately will improve patient safety. Preopera-
tive smoking cessation also has the advantage of promoting 
long-term smoking abstinence (Rigotti et al. 2008, Thomsen 
et al. 2009). However, it is somewhat concerning that smok-
ing cessation funding is currently being substantially reduced 
or removed altogether in some areas of England (Iacobucci 
2018b), which will undoubtedly influence who has access 
to this evidence-based support and the quality of it. Eligible 
arthroplasty patients who are unable to quit smoking despite 
undergoing cessation therapy will also continue to pose a 
dilemma. Although there is no clear evidence as to what to do 
in these circumstances, it is advised that the surgeon reconsid-
ers the indication for surgery and balances the benefits and 
risks together with the patient, anesthesiologist, and other rel-
evant healthcare professionals.
Strengths and limitations
This is by far the largest study assessing the effect of smoking 
on outcomes following arthroplasty. We suspect the findings 
are generalizable to many Western populations. Contrary to 
other studies, we have importantly considered outcomes in 
ex-smokers, subdivided the cohort into THA and TKA, and 
explored short-term and long-term postoperative outcomes, 
including PROMs, implant and patient survival, and medica-
tion usage. Therefore our findings provide the most compre-
hensive picture of the outcomes patients will achieve follow-
ing arthroplasty based on smoking status, and they provide 
useful information for healthcare professionals when counsel-
ling patients regarding the relative risks associated with each 
arthroplasty procedure.
Using observational data means we cannot infer causality. 
Although the validity of clinical diagnoses in CPRD is high 
(Herrett et al. 2010), it is possible that some inaccuracies in 
coding exist within the dataset analyzed. We acknowledge 
that a limitation of using routinely available data from primary 
care is that information on smoking status is captured broadly 
in only 3 categories. Also, more detailed information on this 
exposure (cigarettes per day, tar and tobacco content etc.) was 
not available. Thus it was not possible to analyze any poten-
tial dose–response relationship related to the outcomes. Given 
the length of time since stopping smoking was not known, by 
categorizing the short-term quitters together with long-term 
quitters it is possible this could increase the complication rate 
for the total ex-smoking group, thereby reducing a difference 
between the ex-smoking and smoking groups. We also recog-
nize that former smoking may be under-recorded in CPRD, 
which may influence the findings in this particular group 
(Booth et al. 2013). 
Some variables had missing data, which may have affected 
the findings. Most incomplete variables only had a small 
proportion of missing data. However, the later introduction 
of PROMs into HES (and availability of only 6-month post-
surgery PROMs) means that much fewer patients had PROMs 
available. Thus care should be taken when interpreting results 
relating to PROMs. Some outcome measures, such as revi-
sion, can be underestimated (Sabah et al. 2016), but there is no 
reason to suspect any underestimation would differ between 
the exposure groups. Although we identified differences in 
all-cause mortality between smoking groups, data were not 
available on cause-specific mortality; therefore we cannot 
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comment on the causes of death and whether they were smok-
ing related. Furthermore, given how the CPRD population 
was selected, our findings may not apply to other populations 
worldwide with different patient characteristics and/or health-
care practices.
Conclusions
This large observational cohort study demonstrated that smok-
ers gain benefit from arthroplasty, with clinically meaningful 
PROM improvement and no increased revision risk. How-
ever, smoking was associated with more medical complica-
tions, analgesia usage, and death following arthroplasty. Most 
adverse outcomes were reduced in ex-smokers compared with 
smokers, suggesting that preoperative smoking cessation may 
improve outcomes following arthroplasty and thus should be 
encouraged by healthcare professionals. 
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